Lymphact Overview

  • Founded
  • 2013
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Lymphact General Information

Description

Provider of personalized medical treatments designed to focus on the treatment of cancer. The company's offers treatments through a technology platform that can generate autologous and allogeneic cellular immune therapies to target not only cancer and virus-infected cells, but also chemotherapy-resistant cancer stem cells and viral reservoirs for clinical applications, thereby enabling patients to get rid of chronic viral diseases quickly and painlessly.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Delivery
Primary Office
  • Zona Industrial De Cantanhede
  • Coimbra, 3060-197
  • Portugal
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Lymphact Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Merger/Acquisition 30-May-2018 000.00 Completed Startup
3. Accelerator/Incubator 000.00 Completed Startup
2. Accelerator/Incubator 14-Sep-2013 $57.9K Completed Startup
1. Seed Round 01-May-2013 $57.9K $57.9K Completed Startup
To view Lymphact’s complete valuation and funding history, request access »

Lymphact Former Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Biocant Park Accelerator/Incubator Minority 000 0000 000000 0
Bynd Venture Capital Venture Capital Minority 000 0000 000000 0
Lisbon Challenge Accelerator/Incubator Minority 000 0000 000000 0
PME Investimentos Investment Bank Minority 000 0000 000000 0
Portugal Ventures Venture Capital Minority 000 0000 000000 0
To view Lymphact’s complete investors history, request access »